ARGX
argenx SE
as 11-22-2024 4:00pm EST
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
More About Our ARGX ML Model...
What kind of parameters do you use to train ARGX stocks ML model?
To train our stocks ARGX ML model, we use historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other metrics.
How often do you update ARGX ML model?
We update our ML model either weekly or biweekly, depending on the market capitalization of the stocks, using TensorFlow, typically over the weekend.
Why is the accuracy of your ARGX model low?
Unfortunately, our current data provider offers limited historical data, which impacts the accuracy of our ML model. However, as we continue to gather more data over time and add more indicators, we expect the accuracy of our model to improve.
How can I provide and share more data with you to increase your ML model accuracy?
We would greatly appreciate your contribution. Please send an email to [email protected]
Do you offer an ML model for shorter time periods, such as 5 minutes or 15 minutes?
Yes, we offer it for strategy purposes only, with intervals: 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes etc.
Can I rely on your ML model to make financial decisions regarding buying or selling stocks, or is it only intended for learning purposes?
Our ML model is primarily designed for educational purposes and is not intended to provide financial advice. We strongly recommend consulting with a financial advisor before making any buying or selling decisions.
Share on Social Networks:
Disclaimer
Our ARGX ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"ARGX Forecast & Prediction for November 24, 2024 argenx SE" should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.